• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Dr. Christoph Hölscher
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

No compulsory license for cholesterol-lowering drugs

17. June 2019

The German Federal Supreme Court has confirmed the decision of the BPatG not to grant a provisional compulsory licence for a patent for cholesterol-lowering drugs. There is no public interest in the granting of a compulsory licence, since there are equivalent medicines.

Background: Action for compulsory licence

compulsory license for cholesterol-loweringBackground to the decision is a claim for a compulsory license for the European patent 2 215 124 (DE 60 2008 042 526) of a US pharmaceutical company with the active ingredient alirocumab. The plaintiffs in the compulsory license action at the Federal Patent Court (BPatG) were the pharmaceutical manufacturers of Praluent®, various companies of a French pharmaceutical group. The plaintiffs wanted to obtain a compulsory license for the disputed patent, which would enable them to use the drug in the Federal Republic of Germany. Last year, the BPatG rejected the granting of a compulsory patent license for the active substance Alirocumab (3 LiQ 1/18 (EP) – we reported).

No compulsory licence for equivalent medicines

As the Federal Patent Court had already pointed out in its ruling, a compulsory license is not justified because patients also have access to equivalent drugs – for example the drug Repatha® from the US patent holder. The Federal Supreme Court stated that neither the reduction in the mortality rate of hypercholesterolemia patients through the administration of Praluent nor the reduction in the mortality rate of patients treated with a PCSK9 inhibitor had been made credible. The clinical studies conducted to demonstrate the reduction of mortality rates were not statistically significant.

Licensing efforts not sufficient

In addition, the Federal Supreme Court ruled in accordance with the BPatG judgment that the applicants had not made sufficient efforts within a reasonable period of time before filing the compulsory license action to obtain a patent usage permit from the respondent.

Both courts made it clear that the applicants should have started their efforts to obtain a usage permit earlier. It is indeed a question of individual case assessment which efforts are necessary under Sec. 24 (1) No. 1 Patent Law and over which period they must extend. However, the applicants had offered only late and only a very low licence rate. In its reply, the respondent had not in principle refused to grant a licence, but the applicants had not reacted until the decision of the patent court.

Compulsory license in the German jurisdiction

In its decision of 11 July 2017, the Federal Supreme Court confirmed the decision of the Federal Patent Court, which for the first time in the history of the Federal Republic of Germany granted a compulsory patent license in summary proceedings (we reported: Compulsory licence: BPatG grants licence to use AIDS drug). The compulsory license permits the provisional manufacture and sale of the antiretroviral HIV/AIDS drug Isentress with the active ingredient Raltegravir, which has been marketed in Germany since 2007. With this ruling, the BGH placed a very high value on public interest and public health care.

In its “Isentress” judgment, the BGH clarified that the licence seeker must have tried over a certain period of time in an appropriate manner to reach an agreement with the patent holder on the granting of a licence. The BGH ruled that only conditions for the granting of licences can be demanded which a reasonable and economically acting third party would be prepared to bear in its place.

The current Praluent judgment follows this case law and adds an important aspect to it. The BGH clarified that no compulsory license is granted if equivalent drugs are available for the treatment. In addition, it became clear that clinical studies to prove the improvement for the patients must show statistically reliable results.

Do you have any questions about licensing or compulsory licensing?

Our attorneys have many years of experience in the pharmaceutical field and are authorized to represent you before any court in Germany as well as internationally.
Please feel free to contact us if you are interested.


 

 

 

Sources:

Press release BGH judgment of 4. June 2019 – X ZB 2/19

The judgment has not yet been published.

Image:

geralt / pixabay.com / CCO License

  • share  
  • share 
  • share 
  • tweet 
  • share 

Category iconHealthcare & Lifesciences,  Licenses Tag iconRepatha,  Federal Supreme Court,  compulsory license,  drug,  Medical Patent,  BGH,  equivalent medicines,  BPatG,  cholesterol-lowering,  Praluent

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022
  • EOS lip balm no 3D trademark – appeal before ECJ not admissible 24. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

6. December 2021
Bioabsorbable medical devices: Advertising permitted

Bioabsorbable medical devices: Advertising permitted

26. November 2021
ECJ: Marketing authorisation of medicinal products according to national rules

ECJ: Marketing authorisation of medicinal products according to national rules

25. October 2021
ECJ: decompiling software to correct bugs

ECJ: decompiling software to correct bugs

15. October 2021
Amendments in patent act China relating Pharmacy

Amendments in patent act China relating Pharmacy

5. October 2021
Merck and Merck & Co: dispute over digital global perception

Merck and Merck & Co: dispute over digital global perception

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Torhaus Westhafen
Speicherstrasse 59
D – 60327 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]